Piper Sandler raised the firm’s price target on Guardant Health (GH) to $120 from $90 following quarterly results. The firm keeps an Overweight rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health Completes $402.5M Convertible Notes Offering
- Cathie Wood Buys the Dip in Pinterest (PINS), Sells Roku and Robinhood Stocks
- Guardant Health announces Shield blood-based screening test results
- Guardant Health 3.33M share Spot Secondary priced at $90.00
- Guardant Health announces $250M common stock offering